Upon reading following paper: https://pubmed.ncbi.nlm.nih.gov/31727409/, I saw that the power analysis is based on a two-sample t-test, while the primary endpoint is based on ANCOVA analysis (with two groups: placebo vs treatment and baseline liver fat as a covariate).

Is it OK to perform a power analysis for a two-sample t-test while not using the same statisitical approach afterwards for the primary endpoint?

Secondly: is the p-value of 0.05 valid for the calculated power when there was an amendment of the protocol (two dosing groups became one dosing group)?

==> the authors write

"Around 117 patients, randomly assigned to 80 mg (two-thirds) or placebo (a third) treatments, and given an estimated treatment difference of 30% change in hepatic fat fraction from baseline to week 12 between any dose of resmetirom and the placebo group and a common SD for the percent change in hepatic fat fraction of 35%, would provide 90% power with a two-sample t test to achieve a significance of 0·025 for a two-dose multiplicity (after protocol amendment, the significance level was reset at 0·05 because a singledose group was used)."

Thanks in advance!

Similar questions and discussions